Our Corporate team has advised Shore Capital (Nomad and joint broker) and Baden Hill (joint broker) on a Placing to raise £9.1 million and an Open Offer to raise a further £2.9 million for AIM-listed company, Oxford BioDynamics plc.
Oxford BioDynamics plc is a biotechnology company developing targeted clinical diagnostic tests for immune health based on the EpiSwitch® 3D genomics platform. The funds will help facilitate working capital to accelerate the commercialisation of its vital 'EpiSwitch®' product line. EpiSwitch® CiRT is a first-of-its-kind precision medicine test that predicts a cancer patient's likely response to Immune Checkpoint Inhibitors (ICIs).
The Gowling WLG team was led by corporate partner, Jeff Elway, assisted by associate, Abby Parkin.
Commenting, Jeff said:
"We are delighted to be involved in another equity fundraising in the Life Sciences sector, with Oxford BioDynamics' flagship product being such a vital service in the ongoing fight against cancer. The fundraise is at a significant premium to the company's recent share price, demonstrating investors' continued belief in the value of the company and its products."
Gowling WLG's global corporate practice offer a complete range of services, from domestic and cross border M&A, private equity and joint ventures through to complex reorganisations, providing industry-leading legal support and sector expertise to deliver on clients' objectives.